Calquence for Mantle Cell Lymphoma User Reviews
Calquence has an average rating of 9.3 out of 10 from a total of 3 reviews for the treatment of Mantle Cell Lymphoma. 100% of reviewers reported a positive experience, while 0% reported a negative experience.
- Chester
- Taken for 1 to 6 months
- August 30, 2023
"So far, no major issues. I have been using it for about 4 months now, since Imbruvica was pulled for mantle cell lymphoma treatment. Bowels move a bit differently than with Imbruvica, but not enough so as to be a problem. My doctors seem to be well satisfied with the way it is working, holding the lymphoma in check if nothing else."
- Nancy...
- Taken for 1 to 6 months
- May 14, 2024
"Minor side effects very manageable. I highly recommend trying Calquence!"
Frequently asked questions
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
More about Calquence (acalabrutinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (18)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: BTK inhibitors
- Breastfeeding
- En español
"My latest PET Scan showed that Calquence is working to reduce MCL activity. Side effects mostly occurred when I started the medication and they were brief. These included fatigue, tinnitus in my left ear, lower appetite and weight loss. My weight is now stable, although down about 13 pounds from when I started. But I’m ok with that, since it’s a better weight for me. I do have some rashes, which my oncologist says it’s due to the medication."